索拉非尼和肝动脉灌注化疗的对比研究与门静脉癌栓晚期肝

StephenW

Journal of Gastroenterology
April 2015, Volume 50, Issue 4, pp 445-454
Date: 16 Jul 2014
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

    Do Seon Song, Myeong Jun Song, Si Hyun Bae, Woo Jin Chung, Jae Young Jang, Young Seok Kim, Sae Hwan Lee, Jun Yong Park, Hyung Joon Yim, Sung Bum Cho, … show all 12




Abstract
Background

The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).
Methods

A total of 110 patients were observed between February 2008 and May 2013 in seven Korean centers. Fifty patients were treated with HAIC, and 60 patients were treated with sorafenib.
Results

The disease control rate in the HAIC was significantly higher than that in the sorafenib group (p < 0.001), although there was no significant difference in the objective response rate (p = 0.214). The median overall survival (OS) was significantly longer in the HAIC group than in the sorafenib group (7.1 vs. 5.5 months, p = 0.011). The median time to-progression (TTP) was also significantly longer in the HAIC group than in the sorafenib group (3.3 vs. 2.1 months, p = 0.034). In the multivariate analysis, tumor diameter (≥ 10 cm) and the absence of combined loco-regional treatment were significant prognostic factors influencing OS (p = 0.002 and p = 0.010, respectively) and TTP (p = 0.017 and p = 0.006, respectively). The treatment modality tended to be a significant prognostic factor for survival (p = 0.052), but not for tumor progression (p = 0.121).
Conclusions

HAIC is comparable with sorafenib in terms of OS and TTP in advanced HCC patients with PVTT. HAIC shows more favorable treatment responses compared with sorafenib. Therefore, HAIC might be an alternative treatment modality to sorafenib in advanced HCC patients with PVTT.
Journal of Gastroenterology Journal of Gastroenterology Look

StephenW

华人消化杂志
2015年4月，第50卷，第4期，第445-454
日期：2014年7月16日
索拉非尼和肝动脉灌注化疗的对比研究与门静脉癌栓晚期肝癌

    做善歌，明洞宋军，思玄裴，宇进涌，在荣张，杨锡金，SAE焕利，君永公园，亨俊艳，宋范町...显示全部12




抽象
背景

这项研究的目的是肝动脉灌注化疗（HAIC）和索拉非尼的疗效比较晚期肝癌（HCC）患者的门静脉癌栓（PVTT）。
方法：

共有110例患者在七个韩国中心2008年2月和2013年5月间观察。 50例患者有HAIC治疗，60例患者用索拉非尼治疗。
结果

在HAIC的疾病控制率较显著高于索拉非尼组（P <0.001），虽然没有在客观缓解率（P = 0.214）无显著差异。中位总体生存（OS）是显著越长越HAIC组比索拉非尼组（7.1对5.5个月，P = 0.011）中。的平均时间，进展时间（TTP）也显著越长越HAIC组比索拉非尼组（3.3与2.1个月，p值= 0.034）中。在多变量分析中，肿瘤直径（≥10厘米）和没有合并的局部区域​​的治疗是影响的OS（P = 0.002和P = 0.010，分别）TTP（p值= 0.017和P = 0.006，分别与显著预后因素）。的治疗方式往往是生存（p值= 0.052）一个显著的预后因素，但不为肿瘤进展（p值= 0.121）。
结论

HAIC是索拉非尼在OS和TTP的晚期肝癌患者的门静脉癌栓方面具有可比性。 HAIC显示索拉非尼相比更优惠的待遇反应。因此，HAIC可能是一种替代治疗方式索拉非尼在晚期肝癌患者的门静脉癌栓。
胃肠病学看胃肠病学杂志